PMID- 8965648
OWN - NLM
STAT- MEDLINE
DCOM- 19961203
LR  - 20240109
IS  - 0169-328X (Print)
IS  - 0169-328X (Linking)
VI  - 36
IP  - 2
DP  - 1996 Mar
TI  - Permeability at the blood-brain and blood-nerve barriers of the neurotrophic 
      factors: NGF, CNTF, NT-3, BDNF.
PG  - 280-6
AB  - A comparison was made of the permeabilities of different neurotrophic factors at 
      the blood-brain barrier (BBB) and blood-nerve barrier (BNB) in normal adult rats 
      by quantifying the permeability coefficient-surface area (PS) product after 
      correction for the residual plasma volume (Vp) occupied by the protein in the 
      capillary bed of the nerve endoneurium or different brain regions. The i.v. bolus 
      injection technique was used in the cannulated brachial vein and artery using the 
      same protein radioiodinated with a second isotope of iodine (125I vs. 131I) to 
      separately determine the PS and Vp values. The plasma washout showed a decreasing 
      plasma half-life in the order of brain-derived neurotrophic factor (BDNF) < 
      neurotrophin-3 (NT-3) < ciliary neurotrophic factor (CNTF) < nerve growth factor 
      (NGF). The PS at the BNB for NGF was 1.40 +/- 0.15 x 10(-6) ml/g/s (mean +/- 
      SEM). The other neurotrophic proteins were all significantly higher than NGF 
      (CNTF: 9.5 x ; NT-3: 20.8 x ; BDNF: 18.9 x ). The Vp for NGF at the BNB was 1.92 
      +/- 0.12 microliters/g and was not significantly different from the other 
      proteins except for NGF vs. BDNF (P < 0.05). The PS for NGF at the BBB ranged 
      from 1.5 to 2.7 x 10(-6) ml/g/s for six different brain regions. The PS for CNTF 
      ranged from 6.0 to 8.0-fold higher than NGF; NT-3: 10.6 to 15.2-fold higher; and 
      BDNF: 11.3 to 16.4-fold higher. The Vp values were not significantly different 
      except for CNTF in the hippocampus and cortex (P < 0.05). SDS-PAGE analyses of 
      all the radioiodinated neurotrophic proteins after 60 min of uptake revealed 
      intact protein in the endoneurium and in the six different brain regions with 
      exposure times of 2-42 days. The quantification of the permeability of these 
      neurotrophic proteins provides baseline values for comparison of different 
      protein modifications that enhance the PS while still preserving the neurotrophic 
      activity (e.g., protein glycation; Poduslo and Curran, Mol. Brain Res., 23 (1994) 
      157). Enhanced permeability following modification might allow the use of 
      systematic delivery of these proteins for practical therapeutic treatment of 
      various neurodegenerative disorders.
FAU - Poduslo, J F
AU  - Poduslo JF
AD  - Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA.
FAU - Curran, G L
AU  - Curran GL
LA  - eng
GR  - NS 14304/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Netherlands
TA  - Brain Res Mol Brain Res
JT  - Brain research. Molecular brain research
JID - 8908640
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Ciliary Neurotrophic Factor)
RN  - 0 (Nerve Growth Factors)
RN  - 0 (Nerve Tissue Proteins)
SB  - IM
MH  - Animals
MH  - Autoradiography
MH  - Blood-Brain Barrier/*drug effects
MH  - Brain-Derived Neurotrophic Factor/*pharmacology
MH  - Ciliary Neurotrophic Factor
MH  - Male
MH  - Nerve Growth Factors/*pharmacology
MH  - Nerve Tissue Proteins/*pharmacology
MH  - Permeability/*drug effects
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Time Factors
EDAT- 1996/03/01 00:00
MHDA- 1996/03/01 00:01
CRDT- 1996/03/01 00:00
PHST- 1996/03/01 00:00 [pubmed]
PHST- 1996/03/01 00:01 [medline]
PHST- 1996/03/01 00:00 [entrez]
AID - 0169328X9500250V [pii]
AID - 10.1016/0169-328x(95)00250-v [doi]
PST - ppublish
SO  - Brain Res Mol Brain Res. 1996 Mar;36(2):280-6. doi: 10.1016/0169-328x(95)00250-v.